SAVAWCassava Sciences Inc. Warrant
Data unavailable—Mkt Cap: —P/E: —742d ago
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical t…
Industry Peers
Healthcare$1.06TUSDP/E 39.7
$655.37BUSDP/E 31.5
$470.55BUSDP/E 75.0
$366.84BUSDP/E 119.0
$334.82BUSDP/E 24.0
$339.14BUSDP/E 24.3
$279.18BUSDP/E 22.2
$263.35BUSDP/E 22.2
$260.71BUSDP/E 25.2
$257.68BUSDP/E 24.9
$244.85BUSDP/E 25.1
$250.91BUSDP/E 36.6
$226.05BUSDP/E 26.0
$210.58BUSDP/E 24.9
$188.73BUSD
$174.73BUSDP/E 32.7
$170.97BUSDP/E 9.7
$163.69BUSDP/E 37.8
$159.81BUSDP/E 40.5
$148.61BUSDP/E 47.6
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit-15.65M $
Net Income (TTM)-90.97M $
Revenue/Share—
Last Price—
Fiscal Year End—
MR Quarter—
Employees17
CountryUS
SectorHealthcare
Industry—
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.02
EPS (TTM)—
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-122.27%
ROA-76.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-32.25M $
CapEx (TTM)581.00K $
FCF Margin—
FCF Yield—
Net Debt-82.68M $
Net Debt/EBITDA6.52
Balance Sheet
Debt/Equity—
Current Ratio2.08
Quick Ratio2.06
Book Value/Sh1.317 USD
Cash/Share1.712 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float47.32M
Insiders—
Institutions—
Technical
SMA 503.487 USD
SMA 2004.927 USD
Beta-0.70
S&P 52W Chg15.96%
Avg Vol (30d)—
Avg Vol (10d)909.49K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—